EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study

Robert Paris, Dan Apter, Suresh Boppana, Maria D'Aloia, Nathalie De Schrevel, Jean-Marc Delroisse, Luca Grassano, Adrienne Guignard, Anil A Panackal, Francois Roman, Jing Yu, Elsa M Yunes und 1 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad182 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Robert Paris und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines, GSK, Rockville, Maryland, US. Hauptthemen laut MEDLINE: Coinfection, Cytomegalovirus Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing a vaccine to prevent congenital cytomegalovirus (CMV) infection and newborn disability requires an understanding of infection incidence. In a prospective cohort study of 363 adolescent girls (NCT01691820), CMV serostatus, primary infection, and secondary infection were determined in blood and urine samples collected at enrollment and every 4 months for 3 years. Baseline CMV seroprevalence was 58%. Primary infection occurred in 14.8% of seronegative girls. Among seropositive girls, 5.9% had ≥4-fold increase in anti-CMV antibody, and 23.9% shed CMV DNA in urine. Our findings provide insights on infection epidemiology and highlight the need for more standardized markers of secondary infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoinfectionCytomegalovirus InfectionsAdolescentFemaleHumansAntibodies, ViralCytomegalovirusIncidenceProspective StudiesSeroepidemiologic Studies

Stichwörter der Autor:innen

CMV pp65 qPCRanti-CMV tegument IgG ELISAcytomegalovirusprimary infectionsecondary infection

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Vaccines, GSK, Rockville, Maryland, US.
  • VL-Medi Clinical Research Center, Helsinki, Finland.
  • Departments of Pediatrics and Microbiology, University of Alabama at Birmingham, Birmingham, US.
  • Vaccines, GSK, Rixensart, Belgium.
  • Vaccines, GSK, Wavre, Belgium.
  • Vaccines, GSK, Siena, Italy.

Förderung

  • GlaxoSmithKline Biologicals

Zitieren

APA

Paris, R., Apter, D., Boppana, S., D'Aloia, M., De Schrevel, N., Delroisse, J. M., Grassano, L., Guignard, A., Panackal, A. A., Roman, F., Yu, J., Yunes, E. M., & Dieussaert, I. (2023). Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad182

Vancouver

Paris R, Apter D, Boppana S, D'Aloia M, De Schrevel N, Delroisse JM, et al. Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad182

BibTeX
@article{Paris2023,
  author = {Paris, Robert and Apter, Dan and Boppana, Suresh and D'Aloia, Maria and De Schrevel, Nathalie and Delroisse, Jean-Marc and Grassano, Luca and Guignard, Adrienne and Panackal, Anil A and Roman, Francois and Yu, Jing and Yunes, Elsa M and Dieussaert, Ilse},
  title = {Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad182}
}
Kostenlos starten →